古汉医药集团股份公司2025年度业绩预告

Group 1 - The company forecasts a net profit loss for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1][2] - The financial data related to this earnings forecast has not been audited by the accounting firm, but preliminary communication indicates no significant disagreements between the company and the auditors [2][3] Group 2 - The main reasons for the expected loss include a slight decline in overall gross profit due to industry policy impacts and rising costs of raw material procurement [3] - The company has conducted impairment testing on goodwill and related asset groups from the acquisition of Guangdong Xiantong, leading to the recognition of impairment provisions [3] - The company has also made provisions for credit impairment on receivables based on actual operating conditions and relevant accounting policies [3]